PB1997: DARATUMUMAB, LENALIDOMIDE, BORTEZOMIB, AND DEXAMETHASONE FOR TRANSPLANT-ELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA: OUTCOME AND SAFETY PROFILE FROM A REAL-WORLD SINGLE CENTER EXPERIENCE
H. Elsabah,
N. Kassem,
A. Gulied,
R. Taha,
H. Elomri,
H. Cherif
Affiliations
H. Elsabah
1 Hematology
N. Kassem
2 Pharmacy department, Hamad medical corporation, Doha, Qatar
A. Gulied
2 Pharmacy department, Hamad medical corporation, Doha, Qatar